National surveillance of cancer survival in Iran (IRANCANSURV): Analysis of data of 15 cancer sites from nine population-based cancer registries.

Autor: Nemati S; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran., Saeedi E; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.; Biostatistics Research Group, Department of Health Science, University of Leicester, Leicester, UK., Lotfi F; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran., Nahvijou A; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran., Mohebbi E; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran., Ravankhah Z; Esfahan Cancer Registry, Esfahan University of Medical Sciences, Esfahan, Iran., Rezaeianzadeh A; Shiraz Cancer Registry, Shiraz University of Medical Sciences, Shiraz, Iran., Yaghoobi-Ashrafi M; Mazandaran Cancer Registry, Mazandaran University of Medical Sciences, Sari, Iran., Pirnejad H; Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran., Golpazir A; Kermanshah Cancer Registry, Kermanshah University of Medical Sciences, Kermanshah, Iran., Dolatkhah R; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Alvand S; Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Ahmadi-Tabatabaei SV; Kerman Cancer Registry, Kerman University of Medical Sciences, Kerman, Iran., Cheraghi M; Cancer Registry Section, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Weiderpass E; International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France., Bray F; International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France., Coleman MP; Cancer Survival Group, Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK., Etemadi A; Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Khosravi A; Deputy of Health, Ministry of Health and Medical Education, Tehran, Iran., Najafi F; Department of Epidemiology and Biostatistics, Kermanshah University of Medical Sciences, Kermanshah, Iran., Mohagheghi MA; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran., Roshandel G; Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran., Malekzadeh R; Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Zendehdel K; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2022 Dec 15; Vol. 151 (12), pp. 2128-2135. Date of Electronic Publication: 2022 Aug 06.
DOI: 10.1002/ijc.34224
Abstrakt: Cancer survival is a key indicator for the national cancer control programs. However, survival data in the East Mediterranean region (EMR) are limited. We designed a national cancer survival study based on population-based cancer registries (PBCRs) from nine provinces in Iran. The current study reports 5-year net survival of 15 cancers in Iranian adults (15-99 years) during 2014 to 2015 in nine provinces of Iran. We used data linkages between the cancer registries and the causes of death registry and vital statistics and active follow-up approaches to ascertain the vital status of the patients. Five-year net survival was estimated through the relative survival analysis. We applied the international cancer survival standard weights for age standardization. Five-year survival was highest for prostate cancer (74.9%, 95% CI 73.0, 76.8), followed by breast (74.4%, 95% CI 72.50, 76.3), bladder (70.4%, 95% CI 69.0, 71.8) and cervix (65.2%, 95% CI 60.5, 69.6). Survival was below 25% for cancers of the pancreas, lung, liver, stomach and esophagus. Iranian cancer patients experience a relatively poor prognosis as compared to those in high-income countries. Implementation of early detection programs and improving the quality of care are required to improve the cancer survival among Iranian patients. Further studies are needed to monitor the outcomes of cancer patients in Iran and other EMR countries.
(© 2022 UICC.)
Databáze: MEDLINE
Externí odkaz: